about
Modulation of T-cell activation by malignant melanoma initiating cellsVEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growthTumor initiation in human malignant melanoma and potential cancer therapiesTumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugsThe Cellular Prion Protein: A Player in Immunological QuiescenceCancer stem cells and the tumor microenvironment: interplay in tumor heterogeneityStem cells and targeted approaches to melanoma cureNANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like CellsCancer stem cells in solid tumors: elusive or illusive?The therapeutic promise of the cancer stem cell concept.Identification and targeting of cancer stem cells.Immunity to stemness genes in human cancer.Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinomaPhenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.Association between tumorigenic potential and the fate of cancer cells in a syngeneic melanoma model.Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to comeCancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype.Targeting CD20 in melanoma patients at high risk of disease recurrence.Immunobiology and signaling pathways of cancer stem cells: implication for cancer therapy.Nanog signaling in cancer promotes stem-like phenotype and immune evasionMarkers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progressionCancer stem cell hypothesis: a brief summary and two proposalsMathematical models of immune-induced cancer dormancy and the emergence of immune evasion.Vaccines targeting cancer stem cells: are they within reach?Cellular and molecular chaperone fusion vaccines: targeting resistant cancer cell populations.Cancer stem cells: perspectives for therapeutic targeting.Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets.Effect of downregulation of ZEB1 on vimentin expression, tumour migration and tumourigenicity of melanoma B16F10 cells and CSCs.Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells?Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine.Safety and efficacy study of lung cancer stem cell vaccine.Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells.Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma.Photodynamic therapy-mediated cancer vaccination enhances stem-like phenotype and immune escape, which can be blocked by thrombospondin-1 signaling through CD47 receptor protein.Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck.Evaluation of the immunogenicity of ALDH(high) human head and neck squamous cell carcinoma cancer stem cells in vitro.Heat shock proteins, autoimmunity, and cancer treatment
P2860
Q24595394-383FA6FB-D6E2-4165-B755-921616790A3CQ24606018-2723012D-67F4-4EFD-AFFE-539890A1B7F8Q24634207-A9AE55CB-1D32-4A67-9694-34032A7FA44FQ26777335-0C781E8B-8953-4F12-B4C9-23114BCC8D72Q26782895-71FC161A-84FB-4261-810D-F7615A4DDC1EQ26796292-6EE411C3-D606-4F2F-B8EF-98E958E336FDQ26825014-E2DEB23D-35F5-4832-B9EB-DFC3CBEFED7BQ28078448-2DCB6745-4218-4771-A334-59718FCF6CB1Q28546959-1B2D9985-8350-4460-8F95-BC8F58120BD8Q33349066-59B84C22-0259-4338-BF9A-FD6DA4291085Q33559711-784E5EB7-55F0-4447-AA31-38A9A46F365FQ33921460-F0180884-6E87-4813-BE47-CE3027BDCB74Q33943241-6785354B-43F9-4DED-9735-690E7432E049Q34105741-09CF6E14-3F10-4685-8BA3-6A91D49FB0BDQ34540318-475B2D49-DCB4-4C70-A36E-9EEDDFDD621AQ34692759-A4E51BCE-0222-4A37-AF18-8946291E5869Q35624884-DFBEBD9F-245F-46D2-964A-DE0A2392F116Q35871717-924EE533-3C7A-4373-AFC3-1434210C53F7Q35939451-FBFF88BE-855D-4174-A348-385A6DAAF5C4Q35984406-325D6798-B014-48AD-8EE6-1A52BF190EB0Q36357895-3D7E0BBD-AAD1-42E7-A756-02E6DC323176Q36511536-0DF3346D-41A2-4E50-AE0C-CAA37B07AFC6Q37039289-4BF1AA9B-302B-4FC1-8746-4B4D3C061C5AQ37561421-717A0E34-BAD5-48DF-92D1-33E05CFE0C3AQ37939527-34A52410-1AAA-4EDA-B3A0-959F6EE74EF1Q38107522-EA84F5FE-D3F3-4660-9762-8D81B07F1ED0Q38238005-FFD78B01-BC4A-4CB4-B75F-5D68B4601287Q38239661-FC3D7ABC-92FF-4088-ACDF-32176F093525Q38850621-C3C67248-2E3A-4741-A2B2-995CF8A1FCBDQ39043081-8492B233-50B9-44E1-B74F-586395519E11Q39176046-5AAE0EC8-D5EA-4921-8E61-50C872E71972Q39177284-39CFED39-5EDC-4DCF-85C5-4FD233949E0FQ40161224-3AC33A85-2383-4231-A33B-DB7F7D10433BQ40166620-6ED9B5C4-DB8D-486E-859C-DFBC3E3D5A58Q40267794-6C924259-391A-43B7-8AF6-6C26B3FA016AQ40399058-5EB13566-07BA-4C4B-8FE9-8289E87531BDQ40403603-DEAD8E93-249D-4055-8CB1-8CBE59729686Q42320974-8B4AA2E7-6664-4B9B-97F9-8D330581E0DFQ42415554-761CB4EE-853F-4E77-BC3C-51D6D3BFF465Q42468487-F6F6FA12-601D-4609-B7C5-837BA3E07D4F
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Antitumor immunity and cancer stem cells
@en
type
label
Antitumor immunity and cancer stem cells
@en
prefLabel
Antitumor immunity and cancer stem cells
@en
P2860
P1476
Antitumor immunity and cancer stem cells
@en
P2093
Markus H Frank
Tobias Schatton
P2860
P304
P356
10.1111/J.1749-6632.2009.04568.X
P407
P577
2009-09-01T00:00:00Z